D.E. Shaw & Co
PTCT icon

D.E. Shaw & Co’s PTC Therapeutics PTCT Stock Holding History

D.E. Shaw & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-54,000
Closed -$1.82M – 3920
2018
Q2 		$1.82M Sell
54,000
-1,800
-3% -$56.1K ﹤0.01% 2293
2018
Q1 		$1.51M Buy
+55,800
New +$1.41M ﹤0.01% 2228

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co's PTCT Position: Q1 2026 in Review

D.E. Shaw & Co reduced its PTC Therapeutics (PTCT) stake by 6% in Q1 2026, selling an estimated $7.41M and leaving 1,640,381 shares worth $112M. The position accounts for 0.07% of the portfolio, ranked #336.

D.E. Shaw & Co first reported a position in PTCT in Q2 2014 and has held it in 44 quarters since. The position peaked at $133M in Q3 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • D.E. Shaw & Co held 1,640,381 shares of PTC Therapeutics worth $112M as of Q1 2026.
  • D.E. Shaw & Co sold 104,610 PTC Therapeutics shares in Q1 2026, an estimated $7.41M.
  • PTC Therapeutics made up 0.07% of D.E. Shaw & Co's portfolio in Q1 2026, its #336 holding.
  • D.E. Shaw & Co first reported a position in PTC Therapeutics in Q2 2014 and has held it in 44 quarters since.
  • D.E. Shaw & Co's PTC Therapeutics position peaked at $133M in Q3 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.